Evaluation of the safety of tranexamic acid use in pediatric patients undergoing spinal fusion surgery: a retrospective comparative cohort study.

Background: Pediatric spinal fusion may be associated with significant intraoperative blood loss, leading to complications from transfusion, hypoperfusion and coagulopathy. One emerging strategy to mediate these risks is by utilization of the anti-fibrinolytic agent tranexamic acid (TXA). However, concerns regarding potential adverse reactions, specifically postoperative seizures and thrombotic events, still exist.

Increase in surgeons performing outpatient anterior cervical spine surgery leads to a shift in case volumes over time.

Background: Prior studies have demonstrated an increase in the performance of outpatient anterior cervical surgery. The degree to which this increase is due to volume increase per individual surgeon versus increase in individual surgeons performing outpatient cervical surgery is unknown.

Methods: Patients undergoing anterior cervical discectomy and fusion (ACDF) or cervical disk arthroplasty (CDA) between 2010 and 2018 in NY state were identified.

Immunoglobulin G4-Negative Inflammatory Pseudotumors of the Pancreas.

Inflammatory pseudotumor (IPT) can occur in any organ, but rarely shows pancreatic involvement. While surgical excision has been recommended as the primary treatment for IPT of the pancreas in the past, some authors suggest observation while medical management often results in regression. Corticosteroids, nonsteroidal anti-inflammatory drugs and immunosuppressive therapy have been used to treat IPTs.

Does the Use of an Intra-Articular Local Anesthetic Injection During Total Hip Arthroplasty Reduce Patient Reported Pain Scores or Patient Opioid Consumption?

Background: During primary total hip arthroplasty (THA), some surgeons use an intra-articular injection (IAI) containing 200 mg ropivacaine to target postoperative pain. There is no clear consensus on the efficacy of an IAI alone. The purpose of this study is to evaluate the effect of a 200 mg ropivacaine IAI on pain scores, opioid consumption, and mobility for primary THA patients.